Network-guided TMS for improving memory in early Alzheimer's disease
Using Network-guided TMS to Ameliorate Memory Deficits in Early Alzheimer's Disease
NA · Duke University · NCT04549155
This study is testing a new way to use brain stimulation to see if it can help improve memory in adults with mild cognitive impairment related to early Alzheimer's disease.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 55 Years to 80 Years |
| Sex | All |
| Sponsor | Duke University (other) |
| Locations | 1 site (Durham, North Carolina) |
| Trial ID | NCT04549155 on ClinicalTrials.gov |
What this trial studies
This research tests a novel approach using network-based transcranial magnetic stimulation (TMS) to enhance memory function in adults with mild cognitive impairment (MCI). By utilizing MRI-derived measures of brain connectivity, the study aims to identify optimal target sites for neurostimulation and compare the effects of active TMS against a sham stimulation condition. The goal is to provide evidence for the efficacy of non-invasive treatments to combat cognitive decline associated with Alzheimer's disease. This innovative methodology focuses on the whole-brain network rather than isolated brain regions, potentially leading to more effective interventions.
Who should consider this trial
Good fit: Ideal candidates are English-speaking adults aged 55-80 with a clinical consensus diagnosis of mild cognitive impairment.
Not a fit: Patients with a history of significant neurological disorders or those with conditions that increase seizure risk may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could offer a new non-invasive treatment option to improve memory function in individuals with early Alzheimer's disease.
How similar studies have performed: While previous studies have explored TMS in normative populations, this network-based approach in Alzheimer's-related populations is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Elderly: age between 55-80 * English speaking * Willing to provide consent * Signed HIPAA authorization * Use of effective method of birth control for women of childbearing capacity * Clinical Consensus for MCI Exclusion Criteria: * History of any Axis I DSM-IV disorder * Current or past history of substance abuse or dependence (excluding nicotine) * Women who are pregnant or breast feeding * Intracranial implants (e.g. aneurysms clips, shunts, stimulators, cochlear implants, or electrodes), cardiac pacemakers, or vagus Nerve stimulation device * Increased risk of seizure for any reason, including prior diagnosis of epilepsy, seizure disorder, increased intracranial pressure, or history of significant head trauma with loss of consciousness for ≥ 30 minutes. * Neurological disorder including, but not limited to: space occupying brain lesion; any history of seizures, history of cerebrovascular accident; fainting, cerebral aneurysm, * Dementia, Hungtington chorea; Multiple Sclerosis. * Current use of medications known to lower the seizure threshold and/or affect working memory * Current or past history of substance abuse or dependence (excluding nicotine) * Women who are pregnant or breast feeding
Where this trial is running
Durham, North Carolina
- Duke University Medical Center — Durham, North Carolina, United States (RECRUITING)
Study contacts
- Principal investigator: Simon W Davis, PhD — Duke University
- Study coordinator: Simon W Davis, PhD
- Email: simon.davis@duke.edu
- Phone: 9196841243
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Mild Cognitive Impairment